Aurinia Pharmaceuticals Inc. (AUPH) fundamentals score
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 7.8 out of 10, Mixed fundamentals
- Growth: 7.1/10
- Profitability: 9.0/10
- Financial health: 9.8/10
- Earnings quality: 3.2/10
- Valuation: 8.6/10
Scores are calculated from Aurinia Pharmaceuticals Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10